<DOC>
	<DOCNO>NCT00019409</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Giving radiation therapy head intrathecal chemotherapy may prevent cancer cell spread brain . It yet know treatment regimen effective acute lymphoblastic leukemia . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy head intrathecal chemotherapy plus high dose cytarabine prevent CNS disease child acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Radiation Therapy Head Intrathecal Chemotherapy Plus High Dose Cytarabine Preventing CNS Disease Children With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy toxicity cranial radiation v triple intrathecal chemotherapy plus high dose systemic cytarabine prophylaxis CNS disease child acute lymphoblastic leukemia . II . Compare overall survival rate patient treatment . OUTLINE : This randomize , multicenter study approve center India . All patient receive induction therapy randomize one two treatment arm . Patients assign arm I receive high dose cytarabine cranial radiation patient assign arm II receive cranial radiation high dose cytarabine . Induction 1 : Patients receive vincristine IV day 1 , 8 , 15 , 22 , 29 , oral prednisone day 1-28 , triple intrathecal therapy ( methotrexate , hydrocortisone , cytarabine ; TIT ) day 1 , 8 , 15 , 22 , asparaginase IM every day day 2-20 , daunorubicin IV day 8 , 15 , 29 . Patients achieve remission proceed randomization . Arm I : Induction 2 : Patients receive oral mercaptopurine daily day 1-7 22-28 , cytarabine IV 3 hour every 12 hour 4 dos day 1-2 22-23 , cyclophosphamide IV day 1 22 , TIT day 8 29 . Induction 1 repeat , patient proceed consolidation blood count recover sufficiently . Consolidation : Induction 2 repeat , patient proceed maintenance blood count recover sufficiently . Maintenance 1 : Patients receive vincristine IV daunorubicin IV day 1 ; oral prednisone day 1-7 ; asparaginase IM day 1 , 3 , 5 , 7 ; oral methotrexate week begin day 15 skipping every 4th week , total 12 week ; oral mercaptopurine begin day 15 3 week 4 , total 12 week ; TIT day 1 36 . Maintenance 2 : Patients receive cytarabine IV 3 hour every 12 hour 4 dos day 1-2 , cyclophosphamide IV 30 minute day 1 , methotrexate , mercaptopurine , TIT day 8 36 . A total 6 maintenance course administer , alternate maintenance 1 2 . Arm II : Induction 2 : Patients receive oral mercaptopurine daily day 1-7 15-21 , cyclophosphamide IV 30 minute day 1 15 , intrathecal methotrexate day 1 , 8 , 15 , 22 . Patients receive cranial radiation daily day 4-12 . Induction 1 repeat , patient proceed consolidation blood count recover sufficiently . Consolidation : Patients receive cyclophosphamide IV 30 minute day 1-15 , vincristine IV day 1 15 , oral mercaptopurine daily day 1-7 15-21 , cytarabine subcutaneously every 12 hour 6 dos day 1-3 15-17 . Patients proceed maintenance blood count recover sufficiently . Maintenance : Same maintenance 1 arm I , exclude TIT . A total 6 course administer . All patient follow monthly first 6 month , every month next 6 month , every 3 month next 2 year , every 6 month next 5 year , annually thereafter . PROJECTED ACCRUAL : A total 1100 patient ( 550 per arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically confirm acute lymphoblastic leukemia Greater 25 % lymphoblasts bone marrow No mediastinal localize lymphoblastic lymphoma No single node extranodal site without bone marrow involvement No B cell lymphoma ( Burkitt 's L3 FAB ) No blast cell positive myeloperoxidase No CNS disease PATIENT CHARACTERISTICS : Age : 120 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Other : HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : No prior corticosteroid Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
</DOC>